Small Molecules
25 September 2015
AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End25 September 2015
AbbVie’s ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis25 September 2015
Celgene’s VIDAZA® (Azacitidine for Injection) Receives Positive CHMP Opinion as New Treatment for Elderly Patients with Acute Myeloid Leukaemia25 September 2015
Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union25 September 2015
Macrophage Therapeutics Produces First Two Immunoconstructs25 September 2015
European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma25 September 2015
The Medicines Company Receives CHMP Positive Opinion for IONSYS® to Treat Post-operative Pain in Adult Patients24 September 2015
Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections24 September 2015
Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-0224 September 2015
OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-37524 September 2015
Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis23 September 2015
Scholar Rock presents first data for niche modulator inhibiting myostatin activation and announces SRK-015 as lead drug program23 September 2015
Taiho Oncology, Inc. Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC)23 September 2015
Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain22 September 2015
Concert Pharmaceuticals Announces Results of a Phase 1 Trial That Demonstrates CTP-656 Achieved a Superior Pharmacokinetic Profile to Kalydeco®22 September 2015
Aradigm Corporation Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)22 September 2015
Pharmaxis Releases Successful Results of Phase 1 Clinical Trial for Boehringer Ingelheim Partnered Drug PXS-4728A22 September 2015
Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERSNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports